Thyrocare Technologies Ltd (IN:THYROCARE)
:THYROCARE
THYROCARE Stock Chart & Stats
₹459.10
-₹16.20(-1.70%)
At close: 4:00 PM EST
₹459.10
-₹16.20(-1.70%)
Day’s Range― - ―
52-Week Range₹220.02 - ₹537.97
Previous CloseN/A
Volume114.81K
Average Volume (3M)56.30K
Market Cap
₹57.51B
Enterprise Value₹18.74B
Total Cash (Recent Filing)₹1.92B
Total Debt (Recent Filing)₹246.80M
Price to Earnings (P/E)61.2
Beta0.51
Next Earnings
May 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.68%
Share Statistics
EPS (TTM)4.30
Shares Outstanding159,165,310
10 Day Avg. Volume44,587
30 Day Avg. Volume56,302
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)2.35
Price to Sales (P/S)1.87
P/FCF Ratio8.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)12.2
Revenue Forecast (FY)₹9.48B
Bulls Say, Bears Say
Bulls Say
Centralized Automated Lab Model & DistributionThyrocare's centralized, automated-lab model and extensive collection network create durable unit-cost advantages and quality control. Scale-driven processing enables margin leverage on incremental volumes and a competitive moat in routine diagnostics, supporting long-term cost efficiency and expansion.
Consistent Revenue Growth TrajectorySustained ~21% revenue growth signals persistent demand and successful market penetration in preventive diagnostics. Over a 2-6 month horizon, this trend supports continued scale benefits, investment in test menu expansion, and reinforces the company's ability to convert clinical demand into durable top-line expansion.
Strong Operating Cash Flow And FCF GrowthImproving operating cash flow and positive free cash flow growth indicate high-quality earnings and internal funding capacity. This durable cash generation underpins reinvestment in lab capacity, funds capex without excessive external financing, and enhances financial flexibility for strategic initiatives over the medium term.
Bears Say
Slight Decline In Net Profit MarginA modest reduction in net margins suggests rising operating costs or financial expenses that could erode profitability if persistent. Over several months, sustained margin pressure would reduce free cash flow conversion and limit leeway for pricing investments, marketing, or margin-accretive initiatives.
Significant Ongoing Capital ExpendituresMaterial capex requirements for lab equipment and automation can strain near-term liquidity despite strong cash flow. If capex remains elevated, it can limit discretionary spending, slow return of capital to shareholders, or necessitate external financing that alters capital structure over the medium term.
Small Increase In Total DebtThough overall leverage is low, a recent uptick in debt reduces some balance-sheet cushion. Continued borrowing to fund capex or expansion could raise interest costs and leverage, increasing financial risk if revenue growth or margins moderate over the coming months.
Thyrocare Technologies Ltd News
THYROCARE FAQ
What was Thyrocare Technologies Ltd’s price range in the past 12 months?
Thyrocare Technologies Ltd lowest stock price was ₹220.02 and its highest was ₹537.97 in the past 12 months.
What is Thyrocare Technologies Ltd’s market cap?
Thyrocare Technologies Ltd’s market cap is ₹57.51B.
When is Thyrocare Technologies Ltd’s upcoming earnings report date?
Thyrocare Technologies Ltd’s upcoming earnings report date is May 21, 2026 which is in 49 days.
How were Thyrocare Technologies Ltd’s earnings last quarter?
Thyrocare Technologies Ltd released its earnings results on Jan 28, 2026. The company reported ₹4.3 earnings per share for the quarter, missing the consensus estimate of ₹4.5 by -₹0.2.
Is Thyrocare Technologies Ltd overvalued?
According to Wall Street analysts Thyrocare Technologies Ltd’s price is currently Overvalued.
Does Thyrocare Technologies Ltd pay dividends?
Thyrocare Technologies Ltd pays a Quarterly dividend of ₹2.333 which represents an annual dividend yield of 0.68%. See more information on Thyrocare Technologies Ltd dividends here
What is Thyrocare Technologies Ltd’s EPS estimate?
Thyrocare Technologies Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Thyrocare Technologies Ltd have?
Thyrocare Technologies Ltd has 159,165,310 shares outstanding.
What happened to Thyrocare Technologies Ltd’s price movement after its last earnings report?
Thyrocare Technologies Ltd reported an EPS of ₹4.3 in its last earnings report, missing expectations of ₹4.5. Following the earnings report the stock price went up 1.313%.
Which hedge fund is a major shareholder of Thyrocare Technologies Ltd?
Currently, no hedge funds are holding shares in IN:THYROCARE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Thyrocare Technologies Ltd
Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. It operates in three segments: Diagnostic Testing Services, Imaging Services, and Others. The company conducts various medical diagnostic tests and profiles of tests that focuses on early detection and management of disorders and diseases, including thyroid, growth, metabolism, auto-immunity, diabetes, anaemia, cardiovascular, infertility, COVID, and various infectious diseases. Its profiles of tests include 34 profiles of tests administered under its Aarogyam brand, which offers patients a suite of wellness and preventive health care tests. The company also sells glucometer and glucostrips under the brand name Sugarscan; consumables; and radiopharmaceutical. Thyrocare Technologies Limited was founded in 1996 and is based in Navi Mumbai, India. Thyrocare Technologies Limited is a subsidiary of Docon Technologies Private Limited.
Technical Analysis
Krsnaa Diagnostics Limited
―
Medi Assist Healthcare Services Limited
―
Metropolis Healthcare Ltd.
―
Morepen Laboratories Limited
―
Vijaya Diagnostic Centre Ltd.
―